Антагонисты лейкотриеновых рецепторов в лечении аллергических заболеваний: обзор эффективности монтелукаста


М.В. Леонова (1), Э.Э. Алимова (1), А.С. Дворников (2)

1) Кафедра клинической фармакологии ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, Москва; 2) Кафедра дерматовенерологии ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, Москва
Представлен обзор клинических исследований и мета-анализов по оценке эффективности антагонистов лейкотриеновых рецепторов в лечении аллергических заболеваний: бронхиальной астмы, аллергического ринита, аллергических заболеваний кожи. Монтелукаст – наиболее хорошо изученный препарат данного класса с оптимальной фармакокинетикой; вошел в десятку ТОП-препаратов в 2015 г.

Литература


1. Theron A.J., Steel H.C., Tintinger G.R., Gravett C.M., Anderson R., Feldman C. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J. Imm. Res. 2014;Article ID 608930:16.

2. Iversen L., Kristensen P., Gron B., Ziboh V.A., Kragballe K. Human epidermis transforms exogenous leukotriene A4 into peptide leukotrienes: possible role in transcellular metabolism. Arch. Dermatol. Res.1994;286(5):261–67.

3. Tintinger G.R., Feldman C., Theron A.J., Anderson R. Montelukast: more than a cysteinyl leukotriene receptor antagonist? Sci World J. 2010;10:2403–13.

4. Gobbato N.B., de Souza F.C., Fumagalli S.B., et al. Antileukotriene reverts the early effects of inflammatory response of distal parenchyma in experimental chronic allergic nflammation. Biomed. Res. Int. 2013;2013:523761.

5. Ogawa Y., CalhounW.J. The role of leukotrienes in airway inflammation. J. Allergy. Clin. Immunol. 2006;118(4):789–98; quiz 799–800.

6. Drazen J.M., Israel E., O’Byrne P.M. Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 1999;340:197–206.

7. Ducharme F.M. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ. 2002;324;1545–53.

8. Ducharme F., Schwartz Z., Hicks G., Kakuma R. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst. Rev. 2004;(2):CD003133.

9. Ducharme F.M., Lasserson T.J., Cates C.J. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst. Rev. 2011;5:CD003137.

10. Reiss T.F., Sorkness C.A., Stricker W., Botto A., Busse W.N., Zhang J., Kundu S. Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax. 1997;52(1):45–8.

11. Noonan M.J., Chervinsky P., Brandon M., Zhang J., Kundu S., McBurney J., Reiss T.F. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur. Respir. J. 1998;11(6):1232–39.

12. Reiss T.F., Chervinsky P., Dockhorn R.J., Shingo S., Seidenberg B., Edwards T.B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch. Intern. Med. 1998;158(11):1213–20.

13. Schlick W., Pohl W., Pfeiffer K.P., Aigner K., Forche G., Kneussl M., Zwick H. Evaluation of 3–5 months’ add on therapy with montelukast in patients with non-controlled asthma in Austria: the STAR open-label, real-world, observational study. Curr. Med. Res. Opin. 2010;26(3):561–70.

14. Malmstrom K., Rodriguez-Gomez G., Guerra J., Villaran C., Piñeiro A., Wei L.X., Seidenberg B.C., Reiss T.F. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann. Intern. Med. 1999;130(6):487–95.

15. Price D., Musgrave S.D., Shepstone L., et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N. Engl. J. Med. 2011;364(18):1695–707.

16. Price D., Popov T.A., Bjermer L., Lu S., Petrovic R., Vandormael K., Mehta A., Strus J.D., Polos P.G., Philip G. Effect of montelukast for treatment of asthma in cigarette smokers. J. Allerg. Clin.Immunol. 2013;131(3):763–71.

17. Knorr B., Matz J., Bernstein J.A., Nguyen H., Seidenberg B.C., Reiss T.F., Becker A. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA. 1998;279(15):1181–86.

18. Knorr B., Franchi L.M., Bisgaard H., Vermeulen J.H., LeSouef P., Santanello N., Michele T.M., Reiss T.F., Nguyen H.H., Bratton D.L. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108(3):E48.

19. Szefler S.J., Carlsson L.G., Uryniak T., Baker J.W. Budesonide inhalation suspension versus montelukast in children aged 2 to 4 years with mild persistent asthma. J. Allergy Clin. Immunol. Pract. 2013;1(1):58–64.

20. Amirav I. Real-life effectiveness of Singulair (montelukast) in 506 children with mild to moderate asthma. Isr. Med. Assoc. J. IMAJ. 2008;10(4):287–91.

21. Grzelewski T., Stelmach I. Exercise-induced bronchoconstriction in asthmatic children: a comparative systematic review of the available treatment options. Drugs. 2009;69(12):1533–53.

22. Zhang H.P., Jia C.E., Lv Y., Gibson P.G., Wang G. Montelukast for prevention and treatment of asthma exacerbations in adults: systematic review and meta-analysis. Allergy Asthma Proc. 2014;35(4):278–87.

23. Bourdin A, Gras D, Vachier I, Chanez P. Upper airway 1: Allergic rhinitis and asthma: united disease through epithelial cells. Thorax. 2009;64:999–1004.

24. Nayak A., Langdon R.B. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007;67(6):887–901.

25. Meltzer E.O., Malmstrom K., Lu S., Prenner B.M., Wei L.X., Weinstein S.F., Wolfe J.D., Reiss T.F. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J. Allergy Clin. Immunol. 2000;105(5):917–22.

26. Wilson A.M., Orr L.C., Sims E.J., Lipworth B.J. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin. Exp. Allergy. 2001;31(1):61–8.

27. Grainger J., Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and meta-analysis. Clin. Otolaryngol.2006;31:360–67.

28. Lu Y., Yin M., Cheng L. Meta-analysis of leukotriene receptor antagonist montelukast in the treatment of allergic rhinitis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014;49(8):659–67.

29. Xiao J., Wu W-X., Ye Y-Y., et al. A network meta-analysis of randomized controlled trials focusing on different allergic rhinitis medications. Am. J. Therapeut. 2015;0:1–11.

30. Valovirta E. Managing co-morbid asthma with allergic rhinitis: targeting the one-airway with leukotriene receptor antagonists. World Allergy Organization J. 2012;5(3):S210–S211.

31. Korn D., Van den Brande P., Potvin E., Dramaix M., Herbots E., Peché R. Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. Curr. Med. Res. Opin. 2009;25(2):489–97.

32. Virchow J.C., Bachert C. Efficacy and safety ofmontelukast in adults with asthma and allergic rhinitis. Respir. Med. 2006;100(11):1952–59.

33. Nonaka M., Sakanushi A., Kusama K., Ogihara N., Yagi T. One-year evaluation of combined treatment with an intranasal corticosteroid and montelukast for chronic rhinosinusitis associated with asthma. J. Nippon Med. Sch. 2010;77(1):21–8.

34. Altman K., Chang C. Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema. Clin. Rev. Allergy Immunol. 2013;45(1):47–62.

35. Nettis E., D’Erasmo M., Di Leo E., Calogiuri G., Montinaro V., Ferrannini A., Vacca A. The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field. Mediat. Inflamm. 2010; ID 628171:6.

36. Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–87.

37. Pacor M.L., Di Lorenzo G., Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A doubleblind,placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin. Exp. Allergy. 2001;31(10):1607–14.

38. Di Lorenzo G., D’Alcamo A., Rizzo M., Leto-Barone M.S., Bianco C.L., Ditta V., Politi D., Castello F., Pepe I., Di Fede G., Rini G. Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review. J. Asthma and Allergy. 2009;2:9–16.

39. de Silva N.L., Damayanthi H., Rajapakse A.C., Rodrigo C., Rajapakse S. Leukotriene receptor antagonists for chronic urticaria: a systematic review. Allergy, Asthma & Clin. Immunol. 2014;10:24–30.

40. Sanada S., Tanaka T., Kameyoshi Y., Hide M. The effectiveness of montelukast for the treatment of antihistamine-resistant chronic urticaria. Arch. Dermatol. Res. 2005;297(3):134–38.

41. Di Lorenzo G., Pacor M.L., Mansueto P., Esposito Pellitteri M., Lo Bianco C., Ditta V., Martinelli N., Rini G.B. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J. Allergy Clin. Immunol. 2004;114(3):619–25.

42. Nettis E., Colanardi M.C., Soccio A.L., Ferrannini A., Vacca A. Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. Brit. J. Dermatol. 2006;155(6):1279–82.

43. Wan K.S. Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria. J. Dermatolog. Treat.2009;20(4):194–97.

44. Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J. Allergy Clin. Immunol. 2002, 110(3):484–88.

45. Agcaoili M.L., Sumpaico M.W., Aleta L.A., et al. Montelukast in the treatment of chronic urticaria: a randomized double blind, placebo controlled study. Ann. Allergy Asthma Immunol. 2011;107(5):Suppl. 1.

46. Nettis E., D’Erasmo M., Di Leo E., et al. The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field. Mediat. Inflamm. 2010;Article ID 628171.


Об авторах / Для корреспонденции


Автор для связи: М.В. Леонова – д.м.н., проф., зав. кафедрой клинической фармакологии лечебного факультета ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, Москва; e-mail: anti23@mail.ru


Похожие статьи


Бионика Медиа